^
    12ms
    SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (ASH 2023)
    A single dose of CAR2 Anti-CD38 CAR-T cells was administered 2 days post lymphodepletion with single-agent cyclophosphamide 1. This phase I trial demonstrated that CAR2 anti-CD38 A2 CAR-T cells were generally well tolerated at the Cohort 2 (MTD) dose and demonstrated objective though short responses even in patients progressing after daratumumab and belantamab mafodotin. More clinical studies are needed to optimize the efficacy and tolerability of CAR-T cell therapies for patients with RRMM. This study was completed, and no more patients will be enrolled.
    Clinical • PK/PD data • CAR T-Cell Therapy
    |
    cyclophosphamide • Darzalex (daratumumab) • Blenrep (belantamab mafodotin-blmf) • STI-1492
    almost2years
    Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1b, N=54, Recruiting, Sorrento Therapeutics, Inc. | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    STI-1492
    over2years
    Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1b, N=54, Recruiting, Sorrento Therapeutics, Inc. | Not yet recruiting --> Recruiting | Initiation date: Mar 2022 --> Jul 2022
    Enrollment open • Trial initiation date
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    STI-1492
    over2years
    Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1b, N=54, Not yet recruiting, Sorrento Therapeutics, Inc. | Initiation date: Nov 2021 --> Mar 2022
    Trial initiation date
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    STI-1492
    3years
    Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1b, N=54, Not yet recruiting, Sorrento Therapeutics, Inc.
    Clinical • New P1 trial
    |
    CD38 (CD38 Molecule)
    |
    CD38 expression
    |
    STI-1492